retatrutide peptide dose ("Reta") Dosage, Mechanism & Benefits Retatrutide Dosing Guide: 1-12 mg

But heres the part that often gets overlooked: GLP-1 meds do not cure insulin resistance

In preclinical characterization studies (Coskun et al., 2022, Molecular Metabolism), retatrutide demonstrated potent agonist activity at all three target receptors: GIP receptor : High-potency agonism derived from the GIP backbone scaffold

fMRI studies on other GLP-1R agonists have also provided further evidence of their cognitive effects

EFFECT OF GLP1 RECEPTOR AGONISTS IN PATIENTS ON SGLT2 INHIBITOR THERAPY As discussed earlier, the effect of a GLP-1 RA (efpeglenatide- not available) in patients on an SGLT-2 inhibitor was determined in the AMPLITUDE-O trial (312)

Some patients may be candidates for switching from semaglutide to tirzepatide, but this decision should be made with a physician